Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2879552 in Relapsed/Refractory AML
NCT02177812Phase 1Terminated
- Sponsor
- GSK
- Start
- Aug 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of GSK2879552 in acute myeloid leukemia (AML) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) at 4 weeks, Number of Participants With Dose Limiting Toxicities (DLT) at 4 weeks and 7 more. Started Aug 2014; status: terminated.
02
Drugs
GSK2879552
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02177812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177812.